Redomain
A Modular Antibody+ Platform for Delivery and Protein Elimination
A Programmable Antibody+ Platform Beyond the Liver
At A Glance
Redomain is an emerging innovative biopharmaceutical company focused on the development and breakthrough of antibody+ drug frontier therapies.
We specialize in targeted delivery technology and are committed to providing innovative therapeutic solutions for unmet clinical needs.
Our core team brings years of accumulated expertise and proven success in the full 0-1-10 chain of innovative drug development, combining strong international vision with robust local execution capabilities. Headquartered in the vibrant biotech ecosystem of Suzhou, Redomain continues to build a proprietary intellectual property platform for antibody-drug research.
Our Mission
Programmable delivery and protein elimination across human tissues
Build a scalable Antibody+ platform
Enabling programmable delivery and protein elimination across tissues
Redefine targeted delivery beyond the liver
Precise, cell-specific RNA delivery across extrahepatic tissues
Enable active clearance of extracellular pathogenic proteins
from passive blockade to receptor-driven degradation
Therapeutic Areas of Focus
eTPD & Precision RNA Therapeutics
Leveraging ASGPR to actively clear circulating pathogenic antibodies
From Muscle Validation to Multi-Organ Expansion, Cell-Specific RNA Delivery Addressing High-Value Indications
